Notably, most tumor-infiltrating Tregs and CD4+Teffs displayed activated (CD62Llow) phenotype irrespectively of the DTA-1 treatment (Supplementary Fig. 1a) and elevated GITR expression (Supplementary Fig. 1b), suggesting that TCRs of these cells have been triggered. This evidence concerns the gene CD4 and neoplasm.